8
Small Allosteric Agonists of GLP-1 Receptor for Type 2 Diabetes treatment
University of Science
Small molecule
Metabolic disease
Hit To Lead or Lead Optimization
The Glucagon-Like Peptide 1 Receptor (GLP-1R), a member of Class B family of G-protein coupled receptors (GPCRs), is an effective target for the treatment of type-2 diabetes, and its incretin peptide and varied peptide mimetics are adopted drugs. Despite remarkable anti-diabetic effects, GLP-1R peptide-based agonists are limited by several disadvantages. Up to now, no small-molecule drugs acting as GLP-1R agonists are available in the market. Therefore, novel approaches in developing small-molecule drugs targeting GLP-1R are very desirable for the treatment of type 2 diabetes.